San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Mekonos is raising $24,999,993.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Anil Narasimha played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Mekonos
Building the future of cell therapies on a chip. Mekonos is creating a proprietary cell-engineering platform, using scalable silicon technology, for hyper-precise ex vivo delivery of molecules into any type of cell. Cell & gene therapy markets are growing exponentially. About 40 therapies expected to be approved by the end of 2022, from the 2017 pipeline of 932 development candidates in the US. Next Generation Scalable Cell-Engineering Platform. Mekonos platform solution, Iris, is a System-on-a-Chip that Automates Delivery and enables Multiplexing with Precision.

To learn more about Mekonos, visit http://mekonos.com/

Contact:
Anil Narasimha, Chief Executive Officer
408-857-2014
https://www.linkedin.com/in/anilnarasimha/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved